Enhancement of fat graft survival by bone marrow-derived mesenchymal stem cell therapy.
Zhao J., Yi C., Zheng Y., Li L., Qiu X., Xia W.
Animal Study, published in Plast Reconstr Surg (2013) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Plast Reconstr Surg (2013)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 24165597
- DOI
- 10.1097/PRS.0b013e3182a48b6c
- Citations
- 22
Abstract (original English)
Adipose-derived stem cells can improve fat graft survival, but there is no literature reporting whether bone marrow-derived mesenchymal stem cells enhance fat graft survival. The authors explored the feasibility of enhancing fat graft survival using bone marrow-derived mesenchymal stem cells. Third-passage expanded rabbit bone marrow-derived mesenchymal stem cells were characterized by adipocyte and osteocyte differentiation and by CD29 and CD31 expression. Three were three groups of nude mice in this experiment: group A, mesenchymal stem cells; group B, expanded mesenchymal stem cells; group C, Dulbecco's medium as a blank control. The transplanted mixture contained 0.3 ml of adipose granule and 0.2 ml of cell components of 5×10⁶ cells. Four months later, grafts were harvested, weighed, and analyzed. Expanded cells were successfully isolated and identified by fibroblast-like adherent shape and osteogenic and adipogenic differentiation. The results were 24.6±3.4 percent for CD29 and 1.8±0.4 percent for CD31 in group A, and 45.0±4.9 percent for CD29 and 1.6±0.3 percent for CD31 in group B. Fat graft survival rates were 0.2052±0.0015 g, 0.1761±0.0014 g, and 0.1350±0.0020 g in groups A, B, and C, respectively (p<0.05). Fat grafts in group A exhibited the best survival and morphologic integrity, uniform lipid droplets, and rich blood vessels; those in group B exhibited modest survi
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.